SecBot SecBot
8-K ·Filed May 6, 2026

COR

Cencora, Inc.
NEUTRAL
Impact 5/10
Horizondays Processed6mo ago SEC0001140859-26-000018
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The revenue miss and decelerating growth temper the EPS beat and guidance raise. Watch for execution on the OneOncology integration and the MWI/Covetrus merger to drive margin expansion in H2. The $1B buyback signals management confidence but is not a catalyst on its own given slowing top-line momentum.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$252.74
T+0 close · May 6, 2026 · via day close
Latest settled
+23.19%
T+60 · $311.34
Vs SPY
+21.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $252.74entry
  2. T+1 · 6mo ago +1.16%α +1.49% · $255.66
  3. T+5 · 6mo ago +3.24%α +2.11% · $260.93
  4. T+20 · 6mo ago +4.31%α +1.53% · $263.64
  5. T+60 · 4mo ago +23.19%α +21.12% · $311.34

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cencora reported fiscal Q2 2026 adjusted diluted EPS of $4.75, slightly above the $4.73 consensus estimate, on revenue of $78.4B (below the $81.04B consensus). The company raised its full-year adjusted EPS guidance range to $17.65-$17.90 from $17.45-$17.75 and announced a $1B share repurchase plan. However, revenue growth decelerated to 3.8% YoY (vs 5.5% in Q1), and adjusted operating income growth slowed to 6.0% (vs 11.9% in Q1), signaling maturing momentum in the core distribution business.

Key Financial Metrics

EPS
$4.75
est $4.73 · +0.4%
Revenue
$78.4B
est $81.0B · -3.3% · +3.8% YoY
Rating
in line
Guidance
4% to 6% growth
raised
Gross Margin
4.58%

Key Facts

  • Adjusted diluted EPS of $4.75 vs consensus $4.73 (beat by 0.4%)
  • Revenue of $78.4B vs consensus $81.04B (miss by 3.3%)
  • Revenue growth slowed to 3.8% YoY from 5.5% in Q1
  • Adjusted operating income growth slowed to 6.0% from 11.9% in Q1
  • Full-year adjusted EPS guidance raised to $17.65-$17.90 from $17.45-$17.75
  • Company expects to repurchase $1B in shares by end of calendar 2026
  • Quarterly dividend maintained at $0.60 per share
  • Completed acquisition of OneOncology in February 2026
  • Signed definitive agreement to merge MWI Animal Health with Covetrus
  • Signed definitive agreement to acquire EyeSouth Partners retina business

Financial Impact

Adjusted EPS beat by $0.02 (0.4%); revenue miss of ~$2.6B (3.3%); guidance raised by $0.15-$0.20 at midpoint

revenueepsoperating incomeshare repurchases

Risk Factors

  • Revenue growth deceleration to 3.8% from 5.5% signals maturing core distribution business
  • Revenue miss of 3.3% vs consensus may pressure the stock near-term
  • Interest expense increased 35.1% YoY due to debt-financed acquisitions
  • Operating cash flow negative $966.5M in H1 due to working capital needs
  • International segment operating income declined 0.6% on a six-month basis

Market Snapshot

Exchange
NYSE
Sector
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Analyst Consensus
79% bullish (19 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140859-26-000018
Document: abc-20260506.htm0001140859-26-000018
Document: 0001140859-26-000018-index-headers.html0001140859-26-000018
Document: 0001140859-26-000018-index.html0001140859-26-000018
Document: 0001140859-26-000018.txt0001140859-26-000018
8-K Data (Synthetic)0001140859-26-000018

Track record

12 reports on COR

Performance horizon

1 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +6.03% at T+20 after the Aug 5, 2026 report. 1 of 4 went positive at some point.

Filters
  1. Nov 4, 202612d ago 8-K Neutral 2/10 Entry $354.00 to $339.68 Now $359.03 +1.42% ▼ −4.05% +0.36% vs SPY
  2. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $354.00 to $339.68 Now $359.03 +1.42% ▼ −4.05% +0.36% vs SPY
  3. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $340.43 to $338.48 Now $359.03 +5.46% ▼ −0.57% +0.61% vs SPY
  4. Oct 20, 202627d ago Institutional Cluster Mixed 3/10 Entry $340.43 to $338.48 Now $359.03 +5.46% ▼ −0.57% +0.61% vs SPY
  5. Sep 25, 20267w ago 8-K Neutral 2/10 Entry $306.92 to $303.81 Now $359.03 +16.98% ▼ −1.01% −0.27% vs SPY
  6. Aug 21, 202612w ago Institutional Cluster Mixed 6/10 Entry $318.04 to $323.77 Now $359.03 +12.89% ▲ +1.80% +2.10% vs SPY
  7. Aug 5, 202614w ago 8-K Neutral 3/10 Entry $317.22 to $325.01 Now $359.03 +13.18% ▲ +2.46% +2.62% vs SPY
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $317.22 to $325.01 Now $359.03 +13.18% ▲ +2.46% +2.62% vs SPY
  9. Jun 15, 202622w ago 8-K Neutral 2/10 Entry $281.46 to $277.09 Now $359.03 +27.56% ▼ −1.55% −0.30% vs SPY
  10. May 29, 202624w ago 8-K Neutral 3/10 Entry $264.69 to $264.84 Now $359.03 +35.64% ▲ +0.06% −0.10% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (12h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026